LONDON (Alliance News) - Cambridge Cognition Holdings PLC Friday said Chief Executive Officer Steven Powell bought 30,000 shares at 36 pence per share on Thursday.
Following this purchase, Powell holds 70,541 shares, representing 0.34% of the issued share capital.
Cambridge Cognition said Thursday that it has submitted its CANTAB Mobile product to the US Food & Drug Administration for clearance as a medical device.
This product was developed to detect episodic memory impairments in early stage Alzheimer's disease patients aged over 50. The company said, following its establishment of a commercial team in the US in 2015 to drive sales, this submission markets the "first step" in broadening out its healthcare technologies into the American market.
Shares in the neuropsychological tests developer were down 7.4% at 36.11p Friday.
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2016 Alliance News Limited. All Rights Reserved.